Roche, InterMune a Strategic Play in Midst of Inversions
Daniel Welch, CEO of Triangle at the time, was a key player in the transaction. Soon after his gig was up at Triangle, Welch joined InterMune as president and CEO.
Mon Aug 25, 2014
Roche pays $8.3bn for drug's potential
Swiss pharmaceutical company Roche Holding has agreed to buy US biotech company InterMune for $8.3 billion in cash in order to get hold of a promising respiratory drug, in the latest multibillion-dollar deal in a consolidating pharmaceutical and biotechnology sector.
Jason Hope And Google Founders Seek Cures For Heart Disease, Cancer
In 2010, Jason Hope joined Peter Thiel's bold $3.5 million commitment to ending aging by making a $500,000 donation to the SENS foundation at an event Mr, Thiel held for SENS.
Roche And InterMune Beckon Pharma's Summer of Discontent
Steve Brozak is President of WBB Securities, LLC, an investment bank and research firm that specializes in the biotechnology, specialty pharmaceutical and medical device sectors.
'Gold-en' opportunity for job seekers in Co Tyrone
Enterprise, Trade and Investment Minister Arlene Foster has announced that Canadian-based Dalradian Resources Inc. is creating 19 new jobs in County Tyrone to support its gold exploration project there.
Roche Buys Intermune For $8.3 Billion, Pledges To Keep Its Employees
I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today.
Sun Aug 24, 2014
Roche to buy U.S. biotech firm InterMune for $8.3 billion
Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.
Fri Aug 22, 2014
Genentech hunting Silicon Valley startups, technology
Genentech Inc [ROGING.UL] is on the hunt for partnerships and investment opportunities in medical-technology startups, Chief Executive Officer Ian Clark told Reuters, underscoring the industry's growing interest in digital healthcare.
Thu Aug 21, 2014
Genentech CEO wonders if wearables craze is a a bit triviala
Some health industry observers think wearables that measure users' biometrics are the next big thing in health care.
The Journal of Investigative Dermatology
Efficacy and Safety of Omalizumab in Patients with Chronic...
Correspondence: Karin Rosén, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, USA.
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., has been appointed as President and Chief Executive Officer, effective immediately.
Wed Aug 20, 2014
USC Eye Institute study finds African-Americans at higher risk for diabetic vision loss
Study points to need for improved screening and access to treatments for diabetic macular edema, a leading cause of vision loss Rohit Varma, M.D., M.P.H., is the director of the USC Eye Institute and professor and chair of ophthalmology at the Keck School of Medicine of USC.
Mon Aug 18, 2014
The Washington Post
Chugai Rises by Limit After Roche Said to Be in Buyout Talks
Chugai Pharmaceutical Co. jumped by the most in four decades after parent Roche Holding AG was said to be in talks to buy out the Japanese drugmaker to secure full control of its cancer and arthritis drugs.
Sat Aug 16, 2014
The Daily Record
Alzheimer's drug misses goals
An experimental drug from the biotech company Genentech failed to slow mental decline in mid-stage studies on more than 500 people with mild to moderate Alzheimer's disease, but showed some promise in the least-impaired participants who received a higher dose.
Fri Aug 15, 2014
Roche to offer $10 billion for rest of Chugai: Bloomberg
Roche Holding AG is in talks to buy the almost 40 percent stake in Japan's Chugai Pharmaceutical Co Ltd that it does not already own for about $10 billion, Bloomberg reported, citing people familiar with the matter.
Gilead beats back Roche, wins U.K. victory for hepatitis C drug Sovaldi
An arbitration panel ruled Friday that the Foster City-based drug maker's hepatitis C blockbuster Sovaldi did not infringe a 2004 research deal that rival Roche had with Pharmasset Inc. Gilead , led by Chairman and CEO John Martin , bought Pharmasset in 2012 for $11 billion, landing the drug that would become Sovaldi.
Thu Aug 14, 2014
Genentech wins approval to treat advanced cervical cancer
Genentech scored its latest victory Thursday when its drug Avastin won federal approval to treat yet another cancer, advanced cervical cancer.
Richard Scheller's rare African art head to de Young
A rare collection of African art assembled over nearly 30 years by a leading Genentech biochemist will go on display at the de Young Museum in Golden Gate Park in late January, marking the first time the public has seen many of the carved forms and shapes.
Wed Aug 13, 2014
Suitors line up for lung drug developer InterMune
InterMune Inc. , on the cusp of finally winning regulatory approval of its treatment for a fatal lung-scarring disease, may be the hottest acquisition target in biotech.
New York Daily News
Google 'anti-aging' group Calico has a website
Google's ambitious health-meets-tech spin-off, announced last fall by Google chief executive Larry Page, now has a website.